5jw2: Difference between revisions

No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:


==Crystal structure of mithramycin analogue MTM SA-Phe in complex with a 10-mer DNA AGGGATCCCT==
==Crystal structure of mithramycin analogue MTM SA-Phe in complex with a 10-mer DNA AGGGATCCCT==
<StructureSection load='5jw2' size='340' side='right' caption='[[5jw2]], [[Resolution|resolution]] 3.10&Aring;' scene=''>
<StructureSection load='5jw2' size='340' side='right'caption='[[5jw2]], [[Resolution|resolution]] 3.10&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[5jw2]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JW2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5JW2 FirstGlance]. <br>
<table><tr><td colspan='2'>[[5jw2]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JW2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5JW2 FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6O7:PLICAMYCIN,+MITHRAMYCIN+ANALOGUE+MTM+SA-PHE'>6O7</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.1&#8491;</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5jw2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jw2 OCA], [http://pdbe.org/5jw2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5jw2 RCSB], [http://www.ebi.ac.uk/pdbsum/5jw2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5jw2 ProSAT]</span></td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=6O7:PLICAMYCIN,+MITHRAMYCIN+ANALOGUE+MTM+SA-PHE'>6O7</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5jw2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jw2 OCA], [https://pdbe.org/5jw2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5jw2 RCSB], [https://www.ebi.ac.uk/pdbsum/5jw2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5jw2 ProSAT]</span></td></tr>
</table>
</table>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Transcription factors have been considered undruggable, but this paradigm has been recently challenged. DNA binding natural product mithramycin (MTM) is a potent antagonist of oncogenic transcription factor EWS-FLI1. Structural details of MTM recognition of DNA, including the FLI1 binding sequence GGA(A/T), are needed to understand how MTM interferes with EWS-FLI1. We report a crystal structure of an MTM analogue MTM SA-Trp bound to a DNA oligomer containing a site GGCC, and two structures of a novel analogue MTM SA-Phe in complex with DNA. MTM SA-Phe is bound to sites AGGG and GGGT on one DNA, and to AGGG and GGGA(T) (a FLI1 binding site) on the other, revealing how MTM recognizes different DNA sequences. Unexpectedly, at sub-micromolar concentrations MTMs stabilize FLI1-DNA complex on GGAA repeats, which are critical for the oncogenic function of EWS-FLI1. We also directly demonstrate by nuclear magnetic resonance formation of a ternary FLI1-DNA-MTM complex on a single GGAA FLI1/MTM binding site. These biochemical and structural data and a new FLI1-DNA structure suggest that MTM binds the minor groove and perturbs FLI1 bound nearby in the major groove. This ternary complex model may lead to development of novel MTM analogues that selectively target EWS-FLI1 or other oncogenic transcription factors, as anti-cancer therapeutics.
Structures of mithramycin analogues bound to DNA and implications for targeting transcription factor FLI1.,Hou C, Weidenbach S, Cano KE, Wang Z, Mitra P, Ivanov DN, Rohr J, Tsodikov OV Nucleic Acids Res. 2016 Sep 1. pii: gkw761. PMID:27587584<ref>PMID:27587584</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 5jw2" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Hou, C]]
[[Category: Large Structures]]
[[Category: Rohr, J]]
[[Category: Synthetic construct]]
[[Category: Tsodikov, O V]]
[[Category: Hou C]]
[[Category: Anti-cancer agent]]
[[Category: Rohr J]]
[[Category: Dna binding]]
[[Category: Tsodikov OV]]
[[Category: Dna-antibiotic complex]]
[[Category: Ewing sarcoma]]
[[Category: Natural product]]
[[Category: Transcription factor]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA